Sixth Street Specialty Lending (TSLX) : 11-year performance

  

 

TransMedics Group (TMDX) : 6-year performance

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. 

• Sector: Healthcare
• Industry: Medical Devices
• Full Time Employees: 728
• Founded in 1998 
• Headquartered in Andover, Massachusetts.
• https://www.transmedics.com

 

 

 

TransMedics is in the business of providing the technology for organ transplants. Its Organ Care System (OCS) allows donor organs to be preserved in a living and functioning state by supplying oxygenated blood while they are being transported.

The OCS system sidesteps the limitations of using ice to transport organs such as the heart, liver or lungs. Organs placed in ice for extended periods of time are at risk of being damaged. According to the company, the OCS method has an added advantage since the system allows doctors to assess the organ's viability – something that is difficult to do when the organ is metabolically inactive in cold storage.

On Monday, shares rose 7%, extending a winning streak to four days after the FDA gave an investigational device exemption for OCS in a new clinical trial for heart transplants. The two-phase trial will test longer perfusion time (passage of blood) for heart transplants using OCS and assess the system's ability to support heart transplants from donors after brain death. The trial is expected to exceed 650 patients and may be the largest clinical trial conducted for heart preservation for transplant purposes.

===Figma (FIG) began trading on the NYSE on Thur 31 Jul 25

• In 2022 Adobe  agreed to acquire Figma for $20 billion, but the deal fell apart in 2023 after U.K. regulators said the tie-up would likely harm competition. 
• Led by 33-year-old CEO Dylan Field, Figma makes web-based software that allows people to collaborate on slide decks, digital whiteboards and designs for apps and websites.
•  

Figma opened at $85 after pricing 36.9 mln share IPO at $33/share; above the $25-28 expected range;

opened for trading with a staggering 158% gain at $85, and then rocketed as high as $116 before shares were immediately halted.

Figma launches in debut as collaborative design software company joins stablecoin company Circle as blockbuster IPOs 

• A successful IPO was widely anticipated for Figma (FIG), but few could have predicted that its 36.9 mln share IPO would price far above expectations ($33 vs. $25-$28 projected range), open for trading with a staggering 158% gain at $85, and then rocket as high as $116 before shares were immediately halted.
• For some quick background on FIG, the company's core business revolves around its cloud-based design platform, which enables real-time collaboration for product design teams, akin to Google Docs for design workflows. Its flagship product, Figma, facilitates user interface and experience design, prototyping, and design system management, while FigJam, launched in 2021, serves as a whiteboard tool for team brainstorming.
• So, why all the excitement? First, the company's financials are quite impressive. For 1Q25, revenue jumped by 46% yr/yr to $228.2 mln, while net income tripled to $44.9 mln, driven by a 91% gross margin. This growth is fueled by FIG's ability to attract high-value enterprise clients (e.g., Netflix, Stripe, ServiceNow), its scalable SaaS model, and product portfolio expansion, including four new AI-focused tools launched in May 2025.
• Also, the IPO market has reawakened, and investors are looking for new high-growth opportunities -- FIG fits the bill. Although the IPO market is healthy, investment banks are still pricing IPOs cautiously. Based on the meteoric open, it's clear that FIG could have priced its IPO at a much higher price, leaving a lot of money on the table. However, companies and their investment bankers are still a little skittish about deals falling flat once they hit the public markets. With Circle's (CRCL) and FIG's huge opening gains, that trend could be changing soon.

Aura Minerals (AUGO) began trading on the Nasdaq on Wed 16 July 25

Aura Minerals Inc. is a Canadian multi-national mining company that owns and operates gold and copper mines in Honduras, Brazil and Mexico. 

The company is headquartered in the British Virgin Islands, operated from its corporate office in Florida and has its stocks traded on the Toronto Stock Exchange and BDR on the B3.

• Founded: 1946
• Headquarters: Coral Gables, Florida
• Website: auraminerals.com
• Employees: 1,337
• CEO: Rodrigo Barbosa

 Ticker: AUGO

Aura Minerals priced 8.10 mln share IPO at $24.25 per share; 

Stock is already listed on Toronto Stock Exchange and Brazilian Stock Exchange and will now trade on the Nasdaq Global Select Market

 

  

BofA Securities and Goldman Sachs & Co. LLC are acting as Global Coordinators, BTG Pactual and Ita BBA are acting as Joint Bookrunners and Bradesco BBI, National Bank of Canada Financial Markets, RBC Capital Markets and Scotiabank are acting as Co-Managers of the offering.

===CVRx, Inc. (CVRX) reports Positive news on outpatient payment for Barostim

 

• Co announced that the Centers for Medicare and Medicaid Services (CMS) has proposed to keep the Barostim implant procedure as part of the New Technology Ambulatory Payment Classification (APC) 1580, with an associated payment of approximately $45,000 for procedures performed in the outpatient setting. CMS is also soliciting comments about the need for a Level 6 Neurostimulator APC. We expect CMS will publish the 2026 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule in November, which is expected to take effect on January 1, 2026.
• This proposal follows two other positive developments in the last nine months relating to reimbursement rates. As of Oct. 1, 2024, Barostim was assigned to a higher paying MS-DRG for inpatient procedures. In that same month it was announced that Barostim will transition from Category III to Category I CPT codes for physician payments as of Jan. 1, 2026. These reimbursement updates underscore the clinical value of Barostim and reinforce its role in the heart failure care continuum.

==Core Scientific (CORZ) to be acquired by CoreWeave (CRWV)

 

CoreWeave to acquire Core Scientific (CORZ) in an all-stock transaction implying a total equity value of $9 bln, expected to close in the fourth quarter of 2025 

• Under the terms of the merger agreement, Core Scientific (CORZ) stockholders will receive 0.1235 newly issued shares of CoreWeave Class A common stock for each share of Core Scientific common stock based on a fixed exchange ratio.
• Following CoreWeave's successful IPO in March 2025, this acquisition will help CoreWeave verticalize its data center footprint to future-proof revenue growth and enhance profitability.
• Through this acquisition, CoreWeave will own approximately 1.3 GW of gross power across Core Scientific's national data center footprint1 with an incremental 1 GW+ of potential gross power available for expansion.
• As of July 3, 2025, the agreed-upon exchange ratio implies a total equity value of approximately $9.0 billion.
• This is calculated on a fully diluted basis and based on CoreWeave's 5-day VWAP. This represents a $20.40 per share value based on the closing price of CoreWeave Class A common stock as of July 3, 2025, and a premium of approximately 66% to the unaffected Core Scientific closing share price of $12.30 on June 25, 2025.
• The final value will be determined at the time of transaction close.
• Upon close, CoreWeave expects Core Scientific's stockholders' ownership of the combined company will be less than 10%.

Omada Health prices IPO at $19 per share

• Omada Health is set to start trading on the Nasdaq under the ticker symbol “OMDA.”
• It’s the second digital health company to hit the market in a matter of weeks, following Hinge Health’s debut in May.
• The company priced its IPO at $19 a share.

Omada Health is a virtual-first healthcare provider focused on helping individuals manage and improve their health, especially those with chronic conditions like prediabetes, diabetes, hypertension, and musculoskeletal issues. 

The virtual chronic care company said in a press release that 7.9 million shares are being sold in the offering, amounting to $150 million.

Omada, founded in 2012, will trade on the Nasdaq under the ticker symbol “OMDA.” The company filed its initial prospectus in May and updated the document with an expected pricing range of $18 to $20 per share. 

At the IPO price, Omada is worth about $1.1 billion, though that number could be higher on a fully diluted basis. That’s right around its private market valuation from 2022, when Omada announced a $192 million funding round that pushed its valuation above $1 billion.

U.S. Venture Partners, Andreessen Horowitz and Fidelity’s FMR LLC are the largest outside shareholders in the company, each owning between 9% and 10% of the stock.

Circle Internet Group (CRCL) began trading on the NYSE on Thur 5 June 25

Circle Internet Group (CRCL) had a wildly successful debut. After pricing its IPO at $31.00 per share, the global fintech specializing in stablecoins traded as high as $103.75 before closing the session at 83.23.

• Opened at $69 after pricing IPO at $31/share

New York-based Circle issues USD Coin, the second-largest stablecoin and often called USDC. USDC represents about 24% of the total stablecoins market cap, trailing only Tether at around 60%, according to data from crypto exchange Kraken. As of March 31, USDC had $60.1 billion in circulation across 4.9 million wallets.

Stablecoins are crypto tokens intended to hold their value at a certain price point, usually $1, and are backed by another asset.

 

• Circle Internet Group (CRCL) is stormed out of the gate as its upsized 34.0 mln share IPO priced at $31/share, above the expected range of $27-$28, achieving a market valuation of $6.9 bln ($8.1 bln fully diluted). Shares opened at $69, a 122.6% surge, reflecting extraordinary investor demand. The IPO raised $1.054 bln in gross proceeds, significantly exceeding the initial target of $624 mln.
• CRCL is a global fintech specializing in stablecoins, notably USD Coin (USDC), the second-largest stablecoin with a $62 bln market capitalization, trailing only Tether's USDT. USDC, pegged 1:1 to the U.S. dollar, facilitates low-cost, rapid cross-border transactions and serves as a trading and DeFi collateral asset. Circle generates revenue primarily through reserve income, transaction and treasury services, and partnerships. In regard to partnerships, CRCL has a 50% revenue sharing agreement with Coinbase (COIN), a key USDC distributor.
• CRCL's mission is to foster a secure, efficient digital dollar ecosystem, bridging traditional finance and blockchain for payments, commerce, and financial applications. Its regulatory compliance, including a 2015 New York BitLicense, positions it as a trusted player for institutional adoption.
• The company's growth prospects are tied to the expanding stablecoin market, projected to grow as digital payments and DeFi gain traction. USDC's ~25% market share and $62 bln in circulation position it to capture increasing demand for stable, blockchain-based transactions, particularly in cross-border payments and B2B use cases. The pending U.S. stablecoin bill, supported by the Trump administration's pro-crypto stance, could enhance USDC's legitimacy and institutional adoption, though it may invite competition from banks exploring their own stablecoins.
• In 2024, CRCL reported revenue and reserve income of $1.68 bln, a 16.1% yr/yr increase, driven by a 9% increase in average daily USDC in circulation reflecting increased demand for Circle stablecoins related to digital asset trading activity, market share gains as it continues to grow in key markets, as well as expanded strategic partnerships and integrations. However, net income fell 41.8% to $(111.9) mln, reflecting rising costs. Distribution and transaction expenses jumped 40.4% in FY24, outpacing revenue growth, due to COIN's revenue-sharing agreement and third-party distribution costs.

Kymera Therapeutics (KYMR) : atopic dermatitis potential matches Sanofi/Regeneron's blockbuster Dupixent in early biomarker response

Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Monday revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral STAT6 degrader medicine.

The findings significantly surpassed the company’s expectations, demonstrating robust STAT6 degradation and a favorable safety profile, thereby derisking the program, the company said in a press release.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 208
• Founded by Bruce Lee Booth and Nello Mainolfi in September 2015 
• Headquartered in Watertown, Massachusetts
• https://www.kymeratx.com

IPO: Aug 21, 20

 

 

 

 

Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. 

Edible Garden (EDBL) : 3-year performance

 

 

 

==NeurAxis (NRXS) : FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms

CARMEL, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it has received FDA 510(k) clearance for IB-Stim™ for the treatment of Pediatric Functional Abdominal Pain (FAP) associated with Functional Dyspepsia, and FD related Nausea Symptoms, in patients aged 8 to 21 years. This clearance is the second successful expanded FDA indication for IB-Stim, following its initial approval for Functional Abdominal Pain associated with Irritable Bowel Syndrome (IBS). The new indication represents the first treatment ever cleared or approved by the FDA related to functional dyspepsia. It is expected to nearly double the Company’s total addressable market, reinforcing NeurAxis’ leadership in non-invasive, pediatric-focused neuromodulation.

About NeurAxis, Inc.

NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.

US IPO Weekly Recap

Four IPOs and six SPACs debuted this week.  

Global trading platform eToro Group (ETOR) priced its upsized US IPO above the range to raise $620 million at a $4.9 billion market cap. eToro’s platform aims to combine a social network with the ability to trade and invest, all within a regulated, digital investment platform for financial discourse. As of December 31, 2024, eToro had approximately 3.5 million Funded Accounts across its global footprint of 75 countries. The company’s total commission grew 45% in 2024, and its net contribution grew 41%. However, it is dependent on volatile trading volumes and prices, and is subject to varying regulations, especially within the crypto space. eToro finished the week up 23%.

Singapore-based digital asset-focused financing firm Antalpha Platform Holding (ANTA) priced its US IPO at the top of the range to raise $49 million at a $329 million market cap. Antalpha provides financing, technology, and risk management solutions to the digital asset industry. The company is the primary lending partner for Bitmain and provides supply chain financing solutions to institutional and corporate participants in the Bitcoin mining industry, offering loans secured by Bitcoin and Bitcoin mining machines. Its revenue jumped more than three times in 2024, although it demands on volatile crypto demand and prices. It finished the week down 6%.

Singapore-based oil and gas equipment maker OMS Energy Technologies (OMSE) priced its downsized US IPO at the midpoint to raise $33 million at a $382 million market cap. The company manufactures surface wellhead systems and oil country tubular goods, primarily for onshore and offshore E&P activities. OMS has a 10-year agreement with Saudi Aramco, which accounts for a majority of the company’s revenue. It finished the week down 13%.

Autonomous delivery systems developer Arrive AI (ARAI) completed its direct listing this week. Arrive AI is developing autonomous last mile mailboxes, designed to support deliveries done by robots and drones. Arrive AI is also developing a suite of software and services for its mailboxes, including features for scheduling, space optimization, and notifications. The company is in the development stage, and has generated no revenues to date. Its finished the week down 21%.

Six SPACs listed this week. Churchill Capital X (CCCXU), founded by former Citi executive Michael Klein, raised $360 million. Wen Acquisition (WENNU) raised $261 million to target fintech and blockchain. Cohen & Company-backed Columbus Circle Capital I (CCCMU) raised $220 million. Renatus Tactical Acquisition (RTACU), led by the former CEO of Digital World Acquisition, raised $210 million to target tech. Perimeter Acquisition I (PMTRU) raised $210 million to target defense and national security. Thayer Venture Acquisition II (TVAIU), the second blank check company formed by Thayer Ventures, raised $175 million to target travel and transportation.

Life360 (LIF) reported earnings on Mon 12 May 25 (a/h)

 Life360 provides technology for tracking family, pets and valuables. The company sells Tile-brand tracking devices.

• Sector: Technology
• Industry: Software - Application
• Full Time Employees: 455
• Incorporated in 2007
• Headquartered in San Mateo, California
• https://intl.life360.com 

ticker: LIF

 ** charts after earnings **

ticker: LIF

IPO: June 6, 2024

Life360 (LIF) — a provider of tracking services for family, pets and valuables — late Monday beat Wall Street's revenue estimate for the first quarter but came up short on total users. Its full-year sales guidance also was light. Life360 stock fell in extended trading.

The San Mateo, Calif.-based company said it earned 5 cents a share on sales of $103.6 million in the March quarter. In the year-earlier period, it lost 14 cents a share on sales of $78.2 million. Analysts polled by FactSet had expected sales of $101.4 million in the first quarter.

Life360 ended the period with 83.7 million global monthly active users, up 26% year over year. However, analysts were expecting 84.5 million.

The company also added 137,000 accounts to its subscription offering, ending the period with 2.4 million Paying Circles worldwide. A Paying Circle is a group of Life360 members with a paying subscription.

Life360 describes itself as a "family connection and safety company." It sells Tile-brand tracking devices and subscription services for families to keep track of loved ones and valuable items like purses, wallets, car keys and bikes.

Black Rifle Coffee Co. (BRCC) reported earnings on Mon 5 May 25 (a/h)

BRC Inc. operates as a veteran-controlled, non-alcoholic beverage company that uniquely blends high-quality coffee production with military and firearms-themed merchandise.

• Sector: Consumer Defensive
• Industry: Packaged Foods
• Full Time Employees: 551
• Founded in 2014 
• HQ in Salt Lake City, Utah
• https://www.blackriflecoffee.com

IPO: February 10, 2022 via a merger with a special purpose acquisition company, or SPAC, affiliate of SilverBox Capital

ticker: BRCC

 ** charts after earnings **

SALT LAKE CITY--(BUSINESS WIRE)--BRC Inc. (NYSE: BRCC), a Veteran-founded, mission-driven premium beverage company, today announced financial results for the first quarter of fiscal year 2025.

• In Q1 2025, packaged coffee distribution increased by 12.2 percentage points to 50.2% ACV and Ready-to-Drink ("RTD") coffee distribution grew by 5.1 percentage points to 47.9% ACV compared to Q1 2024.
• Wholesale revenue declined 6.0% compared to Q1 2024, primarily due to the net reduction of $8.5 million in prior-year barter transaction revenue.
• Net loss was $7.8 million in Q1 2025, a decrease of $9.7 million compared to net income of $1.9 million in Q1 2024. Adjusted EBITDA was $0.9 million, down $11.6 million from $12.5 million in Q1 2024.

IPOs this week : May 5 - 9, 25 (wk 19)

Aspen Insurance – Hamilton, Bermuda, 11 million shares, priced at $29-$31, managed by Goldman Citi. Proposed NYSE symbol AHL. Business: Bermuda-based global provider of specialty P&C insurance and reinsurance.

American Integrity – Tampa, Fla., 6.9 million shares, priced at $15-$17, managed by KBW Piper Sandler. Proposed NYSE symbol AII. Business: Florida-based provider of personal residential property insurance.

OMS Energy Technologies – Singapore, 5.6 million shares, priced at $8-$10, managed by Roth Cap.. Proposed Nasdaq symbol OMSE. Business: Singapore-based manufacturer of surface wellhead systems and oil country tubular goods.

Apimeds Pharmaceuticals – Hopewell, N.J., 3.5 million shares, priced at $4-$5, managed by D. Boral Capital. Proposed NYSE American symbol APUS. Business: Clinical stage biotech developing bee venom-based treatment for inflammation.

Kandal M Venture – Takhmao, Cambodia, 2 million shares, priced at $4-$5, managed by Dominari Sec. Revere Sec.. Proposed Nasdaq symbol FMFC. Business: Cambodia-based contract manufacturer of affordable luxury leather goods.

AirSculpt Technologies (AIRS) reported earnings on Fri 2 May 25 (b/o)

AirSculpt Technologies provides custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure.

• Sector: Healthcare
• Industry: Medical Care Facilities
• Full Time Employees: 389
• Founded by Aaron J. Rollins in 2012  
• Headquartered in Miami Beach, Florida
• https://airsculpt.com

Ticker: AIRS

** charts after earnings **

 

 

First Quarter 2025 Results

• Case volume was 3,076 for the first quarter of 2025, representing a 17.9% decline from the fiscal year 2024 first quarter case volume of 3,746;
• Revenue declined 17.3% to $39.4 million from $47.6 million in the fiscal year 2024 first quarter;
• Net loss for the quarter was $2.8 million compared to net income of $6.0 million in the fiscal year 2024 first quarter; and Adjusted EBITDA was $3.8 million compared to $7.3 million for the fiscal year 2024 first quarter.

2025 Outlook

The Company projects full year 2025 revenue and adjusted EBITDA guidance as follows:

• Revenues of approximately $160 to $170 million
• Adjusted EBITDA of approximately $16 to $18 million

IPOs this week : Apr 28 - May 2, 25 (wk 18)

AIRO - Albuquerque, N.M., 5 million shares, priced at $14-$16, managed by Cantor Fitz. BTIG. Proposed Nasdaq symbol AIRO. Business: Developer of drones and eVTOL aircraft.

OMS Energy Technologies - Singapore, 5.6 million shares, priced at $8-$10, managed by Roth Cap.. Proposed Nasdaq symbol OMSE. Business: Singapore-based manufacturer of surface wellhead systems and oil country tubular goods.

Bgin Blockchain - Singapore, 6.3 million shares, priced at $7-$9, managed by Chardan Benchmark. Proposed Nasdaq symbol BGIN. Business: Makes equipment for cryptocurrency mining with a focus on alternative coins.

Yuanbao - Beijing, 2 million shares, priced at $13-$15, managed by Goldman (Asia) Citi. Proposed Nasdaq symbol YB. Business: Online distributor of insurance policies in China.

Apimeds Pharmaceuticals – Hopewell, N.J., 3.5 million shares, priced at $4-$5, managed by D. Boral Capital. Proposed NYSE American symbol APUS. Business: Clinical stage biotech developing bee venom-based treatment for inflammation.

==Skye Bioscience (SKYE) : 1-year performance

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. 

The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. 

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 16
• Headquartered in San Diego, California
• https://skyebioscience.com

CBLL : 6-month performance

Ticker: CBLL

Basel Medical Group (BMGL) began trading on the Nasdaq on Tue 25 Feb 25

Basel Medical Group Ltd engages in the provision of healthcare services in Singapore. 

• Sector: Healthcare
• Industry: Medical Care Facilities
• Full Time Employees: 32
• Incorporated in 2023 
• HQ in Singapore
• https://baselmedical.com

IPO: 25 Feb 25;  initial public offering of 2,205,000 ordinary shares at a public offering price of US$4.00 per share

Ticker: BMGL

FatPipe (FATN) began trading on the Nasdaq on Tue 8 Apr 25

FatPipe, Inc. develops secure software-defined wide area network (SD-WAN), secure access service edge (SASE), and network monitoring service (NMS) software solutions for organizations in the United States and internationally.

Operations in the United States, Nigeria, Philippines, Australia, India, and South Africa.

• Sector: Technology
• Industry: Software - Infrastructure
• Full Time Employees: 154
• Founded in 1989
• HQ in Salt Lake City, Utah
• https://www.fatpipeinc.com

Ticker: FATN

Initial public offering of 695,656 shares of common stock at a public offering price of $5.75 per share.

 

Wellchange (WCT) : 6-month performance

Wellchange Holdings Co. Ltd. is a holding company, which engages in the provision of enterprise software solution services. It provides tailor-made software solutions, cloud-based software-as-a-service (SaaS) services, and white-labelled software design and development services. 

• Sector: Technology
• Industry: Software - Application
• Full Time Employees: 7
• Founded in 2011 
• Headquartered in Cheung Sha Wan, Hong Kong
• https://www.wchingtech.com

Ascentage Pharma (AAPG) : 2-month performance

 Ticker:  AAPG

Stablecoin issuer Circle Internet Group, Inc. files for IPO

Circle, the company behind the USDC stablecoin, has filed for a U.S. initial public offering, becoming the latest tech firm that is aiming to test the market as tariff uncertainty and worries about the economy’s health weigh on the stockmarket.

In its prospectus filed with the Securities and Exchange Commission on Tuesday, Circle said it plans to list on the New York Stock Exchange under ticker symbol “CRCL.” A stablecoin is a cryptocurrency whose value is pegged, or tied, to that of another currency, commodity, or financial instrument and so tends to be less volatile than other digital assets like Bitcoin. USDC, which was launched in 2018, is backed by U.S. dollar assets.

Circle, which had previously announced plans to go public in 2021 via a SPAC merger, said in Tuesday's SEC filing that its net income last year was $155.7 million, down from $267.5 million a year earlier. It had $1.68 billion in revenue and reserve income in 2024, versus $1.45 billion in 2023.

Newsmax (NMAX) began trading on the NYSE on Mon 31 March 25

(Bloomberg) — Newsmax Inc.’s (NMAX) debut as a public company has given founder and Chief Executive Officer Christopher Ruddy a fortune of about $3.3 billion after its shares surged 735%.

Sector: Communication Services

Industry: Broadcasting

Full Time Employees: 400

https://invest.newsmax.com

Ticker: NMAX

The conservative cable news network sold $75 million of shares at $10 each in Monday’s initial public offering. The stock closed at $83.51 after repeated trading pauses due to volatility.

Ruddy’s 39.2 million class A shares, owned through a revocable trust, have 10 votes each, giving him control of 81% of the company’s votes. He didn’t sell any shares in the New York Stock Exchange offering.

Other investors include Interactive Brokers Group Inc. founder Thomas Peterffy, who owns 23 million shares worth $1.9 billion through Conyers Investments LLC; Sheikh Sultan bin Jassim Al-Thani, a Qatari royal whose investment firm, Heritage Advisors, owns 19.7 million shares; and Vadim Shulman, a Ukrainian industrialist.

Newsmax’s share price gives the company a market value of more than $10.7 billion. The Boca Raton, Florida-based firm lost $72 million last year on revenue of about $171 million. Fox Corp., which is worth almost $25 billion and operates competing network Fox News, reported net income of $2.4 billion on $6.5 billion of revenue in the same period.

Rupert Murdoch, who is chairman emeritus of Fox Corp., is worth $15.2 billion, according to the Bloomberg Billionaires Index.